Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
NCT ID: NCT06290102
Last Updated: 2025-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2024-05-16
2024-10-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To determine the pharmacokinetic (PK) profile of fluticasone propionate (Fp) and albuterol sulfate (ABS), delivered in combination, from a single dose of TEV-56248 (Fp and ABS multidose dry powder inhaler with e-module \[Fp/ABS eMDPI\]) in participants with asthma
* To compare the PK profiles of Fp for 2 different dose strengths of TEV-56248 to that of fluticasone propionate multidose dry powder inhaler (Fp MDPI)
* To compare the PK profiles of ABS between the 2 different strengths of TEV-56248
The secondary objective is:
• To evaluate the safety of a single dose of TEV-56248 and a single dose of Fp MDPI
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma
NCT02680561
Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler
NCT02980133
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619
A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics
NCT02126839
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence ABC
TEV-56248
Pharmaceutical form: Dry powder
Route of administration: Oral inhalation
Fp MDPI
Pharmaceutical form: Dry powder
Route of administration: Oral inhalation
Sequence BCA
TEV-56248
Pharmaceutical form: Dry powder
Route of administration: Oral inhalation
Fp MDPI
Pharmaceutical form: Dry powder
Route of administration: Oral inhalation
Sequence CAB
TEV-56248
Pharmaceutical form: Dry powder
Route of administration: Oral inhalation
Fp MDPI
Pharmaceutical form: Dry powder
Route of administration: Oral inhalation
Sequence ACB
TEV-56248
Pharmaceutical form: Dry powder
Route of administration: Oral inhalation
Fp MDPI
Pharmaceutical form: Dry powder
Route of administration: Oral inhalation
Sequence BAC
TEV-56248
Pharmaceutical form: Dry powder
Route of administration: Oral inhalation
Fp MDPI
Pharmaceutical form: Dry powder
Route of administration: Oral inhalation
Sequence CBA
TEV-56248
Pharmaceutical form: Dry powder
Route of administration: Oral inhalation
Fp MDPI
Pharmaceutical form: Dry powder
Route of administration: Oral inhalation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TEV-56248
Pharmaceutical form: Dry powder
Route of administration: Oral inhalation
Fp MDPI
Pharmaceutical form: Dry powder
Route of administration: Oral inhalation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has persistent asthma, with a forced expiratory value (FEV1) that is greater than or equal to 80% of the value predicted for age, height, sex, and race at the Screening Visit
* Demonstrate acceptable inhalation technique with the training inhaler
* Able to stop (as judged by the Investigator) his or her rescue medication, for approximately 6 hours before the Screening Visit and for approximately 4 hours before training sessions in periods 1-3
* Has body mass index (BMI) within the 3rd and 97th percentiles for the participant's age and gender. The participant must have a weight of ≥18 kilograms (kg)
* Able to achieve a peak inspiratory flow (PIF) rate of at least 60 liters per minute (L/min) on an inhaler training device
NOTE- Additional criteria apply, please contact the investigator for more information
Exclusion Criteria
* Has participated as a randomized participant in any investigational drug trial within 30 days (starting from the final follow-up visit of that trial) preceding the Screening Visit or plans to participate in another investigational drug trial at any time during this trial
* Known hypersensitivity to any corticosteroid, albuterol, or any of the ingredients in the investigational medicinal product
* Asthma exacerbation requiring systemic corticosteroids within 30 days of the Screening Visit, or has had any hospitalization for asthma within 2 months of the Screening Visit
NOTE- Additional criteria apply, please contact the investigator for more information
4 Years
11 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Teva Medical Expert, MD
Role: STUDY_DIRECTOR
Teva Branded Pharmaceutical Products R&D, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Teva Investigational Site 12010
Mobile, Alabama, United States
Teva Investigational Site 12003
Long Beach, California, United States
Teva Investigational Site 12007
Miami, Florida, United States
Teva Investigational Site 12005
Miami, Florida, United States
Teva Investigational Site 12002
Miami, Florida, United States
Teva Investigational Site 12008
Lafayette, Louisiana, United States
Teva Investigational Site 12011
Columbia, Missouri, United States
Teva Investigational Site 12012
Oklahoma City, Oklahoma, United States
Teva Investigational Site 12001
Boerne, Texas, United States
Teva Investigational Site 12009
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TV56248-RES-10204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.